1
|
Fishbourne E, Ludi AB, Wilsden G, Hamblin P, Statham B, Bin-Tarif A, Brocchi E, Grazioli S, Dekker A, Eblé P, King DP. Efficacy of a high potency O 1 Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa. Vaccine 2017; 35:2761-2765. [PMID: 28396208 DOI: 10.1016/j.vaccine.2017.02.047] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 02/10/2017] [Accepted: 02/11/2017] [Indexed: 10/19/2022]
Abstract
Outbreaks of foot-and-mouth disease (FMD) in North Africa (2013) and the Gulf States (2013) of the Middle East have been caused by a FMD viral lineage (O/ME-SA/Ind-2001) that was before 2013 restricted to the Indian Sub-continent. This study was undertaken to assess the in vivo efficacy of a FMD virus emergency vaccine type O1 Manisa against heterologous challenge with a representative field virus (O/ALG/3/2014) from this emerging lineage. This widely available vaccine was selected since in vitro vaccine-matching results gave inconclusive results as to whether or not it would be protective. Three groups of five cattle were vaccinated with O1 Manisa (homologous potency ≥6PD50/dose) using study guidelines outlined in the European Pharmacopeia, and challenged at 21days post-vaccination by tongue inoculation. All animals that were vaccinated with the lowest dose (1/16) of vaccine developed generalised FMD, defined as vesicular lesions at the feet. One animal vaccinated with a 1/4 dose of the vaccine also developed generalised disease, as did two animals vaccinated with the full dose of vaccine. These results indicate that the heterologous potency of this high potency O1 Manisa vaccine was approximately 3.5 PD50/dose. These data support the use of the O1 Manisa vaccine for FMD control in areas where FMDV is endemic e.g. North Africa, and motivate further studies to evaluate other vaccine candidates (or multivalent combinations) that might be potentially used for emergency purposes in FMD-free settings.
Collapse
Affiliation(s)
- Emma Fishbourne
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, United Kingdom
| | - Anna B Ludi
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, United Kingdom.
| | - Ginette Wilsden
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, United Kingdom
| | - Pip Hamblin
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, United Kingdom
| | - Bob Statham
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, United Kingdom
| | | | - Emiliana Brocchi
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), Via Bianchi, 9, 25024 Brescia, Italy
| | - Santina Grazioli
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), Via Bianchi, 9, 25024 Brescia, Italy
| | - Aldo Dekker
- Wageningen Bioveterinary Research, Laboratory Vesicular Diseases, Department of Virology, Houtribweg 39, 8221RA Lelystad, The Netherlands
| | - Phaedra Eblé
- Wageningen Bioveterinary Research, Laboratory Vesicular Diseases, Department of Virology, Houtribweg 39, 8221RA Lelystad, The Netherlands
| | - Donald P King
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, United Kingdom
| |
Collapse
|